Frequent occurrence of CD19-negative relapse after CD19 CAR T and consolidation therapy in 14 TP53-mutated r/r B-ALL children

[1]  N. Shah.  The one-two punch (of CAR T cells). , 2020, Blood.

[2]  S. Zuo,et al.  Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL. , 2019, Blood.

[3]  Jiali Cheng,et al.  Efficacy and Safety of CAR19/22 T-cell "Cocktail" Therapy in Patients with Refractory/ Relapsed B-Cell Malignancies. , 2019, Blood.

[4]  Jin Gao,et al.  CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia , 2019, Leukemia.

[5]  P. Lu,et al.  A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-Modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia , 2018, Blood.

[6]  K. Davis,et al.  Phase 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL) , 2018, Blood.

[7]  R. Fulton,et al.  TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Yang Feng,et al.  CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL , 2017, Nature Medicine.

[9]  Jf Yang,et al.  High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients , 2017, Leukemia.

[10]  D. Porter,et al.  Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  D. Maloney,et al.  Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. , 2016, Blood.

[12]  Christopher A. Miller,et al.  The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML , 2014, Nature.

[13]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[14]  C. Eckert,et al.  Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.